Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control (Q35758657)

10 August 2017

title

Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control (English)

1 reference

10 August 2017

N Schwab

1 reference

10 August 2017

J C Ulzheimer

1 reference

10 August 2017

R J Fox

1 reference

10 August 2017

T Schneider-Hohendorf

1 reference

10 August 2017

B C Kieseier

1 reference

10 August 2017

C M Monoranu

1 reference

10 August 2017

S M Staugaitis

1 reference

10 August 2017

W Welch

1 reference

10 August 2017

S Jilek

1 reference

10 August 2017

R A Du Pasquier

1 reference

10 August 2017

W Brück

1 reference

10 August 2017

K V Toyka

1 reference

10 August 2017

R M Ransohoff

1 reference

10 August 2017

H Wiendl

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 February 2012

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

page(s)

458-67; discussion 465

1 reference

Clonal composition of neuroantigen-specific CD8+ and CD4+ T-cells in multiple sclerosis.

10 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Mefloquine in the treatment of progressive multifocal leukoencephalopathy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Opportunistic infections and other risks with newer multiple sclerosis therapies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Myelomonocytic cell recruitment causes fatal CNS vascular injury during acute viral meningitis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Three or more routes for leukocyte migration into the central nervous system

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Progressive Multifocal Leukoencephalopathy in Acquired Immunodeficiency Syndrome: Explaining the High Incidence and Disproportionate Frequency of the Illness Relative to Other Immunosuppressive Conditions

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Immunology: In the beginning

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Immune surveillance in multiple sclerosis patients treated with natalizumab.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

JC virus early protein detection by immunohistochemistry in progressive multifocal leukoencephalopathy: a comparative study with in situ hybridization and polymerase chain reaction.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Expression of CCR7 in multiple sclerosis: implications for CNS immunity

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Integrin Receptors Are Crucial for the Restimulation of Activated T Lymphocytes

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280052

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

25 September 2018

1 reference

12 December 2020

Barrier to electrical storms

1 reference

12 December 2020

Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: enigma, wrapped in mystery, enclosed in conundrum

1 reference

12 December 2020

Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions

1 reference

12 December 2020

Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis

1 reference

12 December 2020

T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking

1 reference

12 December 2020

Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes

1 reference

12 December 2020

10.1212/WNL.0B013E3182478D4B

Identifiers

DOI

1 reference

release_2khq4akrbbgi7p7wjoyyekwbhe

10 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2khq4akrbbgi7p7wjoyyekwbhe

24 November 2022

mapped directly with Wikidata item

PMC publication ID

3280052

1 reference

10 August 2017

1 reference